Biosimilar User Fee Agreement Offers FDA Funding Boost, Fee Structure Overhaul

The changes proposed for the second iteration of the Biosimilar User Fee Act program suggest FDA and industry agree the agency needs a massive funding boost to handle an expected crush of applications and provide sponsors with timely regulatory advice on the complexities of biosimilar product development.

Under the FDA-industry negotiated BsUFA II agreement released Sept